Duane Morris‘ work on the sale of startup company client Vicept Therapeutics is evidence that one good deed can lead to another, or, perhaps, one good deal to another.
Philadelphia-based corporate partner Yves Quintin led the firm’s work in 2009 and 2010 on the $350 million sale of client Ception Therapeutics to pharmaceutical company Cephalon . That deal also provided the potential for an additional $500 million in milestone payments.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
